News of Sustaining Members

Military Medicine, Summer 2004

DynPort Vaccine Company LLC (DVC) of Frederick, MD has demonstrated the efficacy of its recombinant plague vaccine. In initial testing, DVC's plague vaccine protected mice against both the bubonic and pneumonic forms of plague, a critical first step in the development of a plague vaccine for human use.

The testing evaluated the efficacy of DVC's recombinant F1V (rF1V) plague vaccine candidate in mice. The immunized mice were challenged with both forms of plague. The study, which began in December 2003 and ended in late February 2004, showed good correlation between the antibody response of the mice and their survival rates.